RMMS recently secured a favorable decision on behalf of its client, Sandoz Inc., in connection with litigation involving Astellas Pharma Inc.’s overactive bladder drug, Myrbetriq® (mirabegron extended-release) Tablets, 25 and 50 mg.
More specifically, on June 9, 2023, Judge Joseph F. Bataillon, sitting by designation at the U.S. District Court for the District of Delaware, held that the asserted claims of U.S. Patent No. 10,842,780 were invalid following a five-day bench trial held in February 2023.
RMMS attorneys appearing for Sandoz included William A. Rakoczy, Rachel Pernic Waldron, Kevin P. Burke, Greg L. Goldblatt, and Steven J. Birkos.